Neuropeptides in human cerebrospinal fluid and in brains of animal models of depression - effects of treatment

Details

Serval ID
serval:BIB_3700339B02D1
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Neuropeptides in human cerebrospinal fluid and in brains of animal models of depression - effects of treatment
Author(s)
Mathé Aleksander A., Nikisch Georg, Agren Hans, Baumann Pierre, El Khoury Aram, Gruber Susanne H.M., Husum Henriette, Jiménez-Vasquez Patricia, Wörtwein Gitta, Andersson Weronica, Aitchison K.J., McGuffin Peter
ISBN
0924-977X
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
16
Series
European Neuropsychopharmacology
Pages
308-309
Language
english
Notes
SAPHIRID:61583
Abstract
Background: Both genes and environment play a role in depressive disorders. While a dysregulation of the monoaminergic systems may be sufficient to cause depression, it is probably not a necessary factor. Indeed, accumulated data indicate that other endogenous compounds, such as neuropeptides, as well as hippocampal cell loss/neurogenesis may be important in pathophysiology and treatment of depression. Thus decreased levels of neuropeptide Y (NPY) have been reported in CSF from depressed patients and consistently with this finding lower NPY, both mRNA and protein, has been measured in hippocampus from both genetic and environmental rat models of depression. Moreover, ECT and SSRIs increase NPY in human CSF and in animals in selected brain regions. With regard to treatment, it is not clear whether early intervention could alleviate or prevent the disorder. Consequently, we studied neuropeptides in I. CSF from depressed inpatients before and after citalopram treatment, and II. brains of animal models: (i) genetic - the Flinders Sensitive Line (FSL) rat and their controls, the FRL line, (ii) environmental - early maternal separation that mimics early life trauma in humans, experiences that predict adult life psychopathology.
Method: In human studies, CSF was collected before and after 5 weeks of citalopram treatment. In animals, early life maternal separation was superimposed on the FSL and FRL rats and behavior studied when the animals reached adulthood, and brain neurochemistry and cell proliferation post-mortem. On postnatal days (PND) 2-14, FSL and FRL pups were maternally separated. Escitalopram or vehicle in food were started on PND 44. Porsolt swim test was done on PND 64−65.
Results: In patients, CRH was decreased and NPY increased following successful citalopram treatment. Strong correlations between CRH decrease, NPY increase and clinical outcome were found. In animals, baseline FSL-FRL differences were found in the Porsolt swim test and in brain neuropeptides: NPY, CGRP, neurokinin A, substance P and CRH in selected brain regions. Cell proliferation was also affected. Moreover, maternal separation and escitalopram also differentiated between the strains.
Conclusions: Both genes and environment play a role in depression but the consequences of early life events are more deleterious in genetically vulnerable individuals. Neuropeptide as well as cell proliferation changes appear to constitute biological correlates of depression and may be markers of treatment. Lastly, results from our animal studies raise a question whether early drug intervention should be explored as a potential strategy to alleviate adult life psychopathology.
Create date
10/03/2008 10:37
Last modification date
20/08/2019 13:25
Usage data